Immune checkpoint inhibitors (ICIs) and molecular targeting drugs used against oncogenic drivers, such as EGFR or ALK, have dramatically changed the treatment of NSCLC.1-6 However, treatment options after those drugs are still limited, and cytotoxic anticancer drugs are the mainstay of subsequent treatment. In addition, because platinum-based combination therapy is the most successful combination with…

Kazuhiko Nakagawa, MD, PhD, is a professor in the Department of Medical Oncology, Kindai University, Faculty of Medicine, in Japan, and he served as the lead principal investigator on the RELAY study, which investigated ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced NSCLC.1 In the following interview, Dr. Nakagawa discusses the trial’s results, as…

By Ben Solomon, MBBS, PhD, FRACP Posted: August 21, 2020 ROS1 rearrangements are found in 1% to 2% of patients with NSCLC. They tend to occur in never smokers and those with adenocarcinoma histology, but molecular testing guidelines recommend testing all patients with non-squamous NSCLC for ROS1 rearrangements regardless of smoking history. Crizotinib was the…

By Kara Nyberg, PhD Posted: June 24, 2020 Given the variable response to immune checkpoint blockade, researchers have long sought to identify predictive biomarkers beyond PD-L1 to better select patients most likely to benefit from such therapy. New work carried out by researchers at the Dana-Farber Cancer Institute has identified a handful of genetic variants…

Letter to the Editor: Opening Trials to Patients Living with HIVBy Armelle Lavolé, AP-HP Hôpital Tenon, Paris, FrancePosted: August 14, 2019 In response to the article by Dr. Jarushka Naidoo, it should be noted that it remains an open question as to whether it is safe to administer immune checkpoint inhibitors (ICI) to people living…

By Mirjana Rajer, MD, PhD Posted: April 1, 2019 For many years, the treatment of patients with stage III lung cancer has been a topic of intense debate among surgeons, radiation oncologists, and medical oncologists. Each discipline has eagerly expected new trials and results to make these discussions clearer and more optimistic. One of the most…

By Richard Booton, MD, PhD, FRCP Posted: April 1, 2019   Dr. Richard Booton   The symptomatic presentation of lung cancer is typically associated with advanced disease and poor survival. Screening asymptomatic at-risk individuals using low-dose CT (LDCT) reduces lung cancer–specific mortality by 20% to 26%,1 but challenges remain in ensuring participation of the most at-risk…